Pictet Asset Management (UK)’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Pictet Asset Management (UK)’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$40.4M	Sell	1,152,686 -1,382,087	-55%	-$54M	0.04%	386
2021 Q1	$103M	Buy	2,534,773 +16,485	+0.7%	+$758K	0.12%	205
2020 Q4	$109M	Buy	2,518,288 +1,311,599	+109%	+$64.7M	0.14%	185
2020 Q3	$66.5M	Buy	1,206,689 +265,764	+28%	+$16.9M	0.1%	228
2020 Q2	$59.4M	Buy	940,925 +348,612	+59%	+$23.9M	0.1%	230
2020 Q1	$30.3M	Buy	592,313 +1,943	+0.3%	+$130K	0.06%	292
2019 Q4	$46.9M	Buy	590,370 +50,860	+9%	+$3.01M	0.08%	278
2019 Q3	$26.2M	Buy	539,510 +100,653	+23%	+$5.25M	0.06%	340
2019 Q2	$23.1M	Sell	438,857 -31,528	-7%	-$1.81M	0.05%	360
2019 Q1	$24.9M	Buy	470,385 +4,326	+0.9%	+$213K	0.05%	356
2018 Q4	$19.1K	Sell	466,059 -8,789	-2%	-$329K	0.05%	381
2018 Q3	$18M	Buy	474,848 +57,775	+14%	+$2.56M	0.04%	438
2018 Q2	$18.9M	Buy	417,073 +103,353	+33%	+$4.71M	0.05%	406
2018 Q1	$15.2M	Buy	+313,720	New	+$17.5M	0.04%	428

Other funds holding GBT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pictet Asset Management (UK)'s GBT Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Global Blood Therapeutics, Inc. (GBT) stake by 55% in Q2 2021, selling an estimated $54M and leaving 1,152,686 shares worth $40.4M. The position accounts for 0.04% of the portfolio, ranked #386.

Pictet Asset Management (UK) first reported a position in GBT in Q1 2018 and has held it in 14 quarters since. The position peaked at $109M in Q4 2020. 191 funds tracked by Wall St. Rank hold GBT as of Q2 2021.

Pictet Asset Management (UK) held 1,152,686 shares of Global Blood Therapeutics, Inc. worth $40.4M as of Q2 2021.
Pictet Asset Management (UK) sold 1,382,087 Global Blood Therapeutics, Inc. shares in Q2 2021, an estimated $54M.
Global Blood Therapeutics, Inc. made up 0.04% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #386 holding.
Pictet Asset Management (UK) first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and has held it in 14 quarters since.
Pictet Asset Management (UK)'s Global Blood Therapeutics, Inc. position peaked at $109M in Q4 2020.
191 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.